Cardiovascular biotech Celladon files for a $86 million IPO

Comment

Shutterstock photo

Celladon, which is developing novel therapies for the treatment of heart disease, filed on Friday with the SEC to raise up to $86 million in an initial public offering. The San Diego, CA-based company, which was founded in 2000, plans to list on the NASDAQ under the symbol CLDN. J.P. Morgan and Barclays are the joint bookrunners on the deal. No pricing terms were disclosed.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: News Headlines , IPOs


More from Renaissance Capital

Subscribe






Renaissance Capital
Contributor:

Renaissance Capital

IPOs
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com